CDK4 and breast carcinoma: For example, CDK4/6 and mTOR inhibitors are approved targeted therapies that have helped prolong survival for many patients with advanced ER+ breast cancers that may have recurred despite endocrine therapy.34 Therefore, identifying novel candidates that can be targeted to suppress growth of endocrine therapy-resistant cancer cells are necessary to continue to improve outcomes for patients.